By Fineline Cube 
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its KH813 in metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
KH813: A Promising Biosimilar
KH813 is a biosimilar version of Merck’s anti-PD-1 therapy Keytruda (pembrolizumab), which is used to treat multiple advanced solid tumors, including non-small cell lung cancer (NSCLC) and melanoma. This approval marks a significant step forward in the development of KH813 and its potential application in cancer treatment.-Fineline Info & Tech